Company Profiles

driven by the PitchBook Platform

GigaGen

Description

Developer of novel monoclonal and polyclonal antibody therapies created to improve outcomes for patients with severe disease. The company uses human B cells1 to capture the genetic diversity of antibodies and transform them into therapies to treat severe diseases. Its novel recombinant monoclonal and polyclonal antibody therapies are discovered from immunized mice against important immuno-oncology targets focusing on sequencing-based immune profiling to predict the occurrence and severity of immune flares in transplant recipients and people with autoimmune disease.

2010

Founded

PRIVATE

Status

1-10

Employees

Corporate

Latest Deal Type

$50M

Latest Deal Amount

$52M

Total Amount Raised

Description

Developer of novel monoclonal and polyclonal antibody therapies created to improve outcomes for patients with severe disease. The company uses human B cells1 to capture the genetic diversity of antibodies and transform them into therapies to treat severe diseases. Its novel recombinant monoclonal and polyclonal antibody therapies are discovered from immunized mice against important immuno-oncology targets focusing on sequencing-based immune profiling to predict the occurrence and severity of immune flares in transplant recipients and people with autoimmune disease.

Website:

www.gigagen.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery

Primary Office

407 Cabot Road South San Francisco, CA 94080United States
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore GigaGen's full profile, request a free trial.

GigaGen Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

GigaGen Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

GigaGen Investors (8)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
BayBio FASTAccelerator/Incubator000 0000000 0000
Claremont Creek VenturesVenture CapitalMinority000 0000000 0000
National Cancer InstituteGovernmentMinority000 0000000 0000
National Institutes of HealthGovernment000 0000000 0000
National Science FoundationGovernment000 0000000 0000
BayBio FAST Accelerator/Incubator
Claremont Creek Ventures Venture Capital
National Cancer Institute Government
National Institutes of Health Government
National Science Foundation Government

GigaGen Executive Team (6)

NameTitleBoard
Seat
Contact
Info
David Johnson Ph.DCo-Founder, President & Chief Executive Officer
Carter KellerChief Operating Officer
Everett Meyer Ph.DCo-Founder & Medical Advisor
Jennifer KellerHead, Marketing
Matthew SpindlerHead, Strategic Alliances
David Johnson Ph.D Co-Founder, President & Chief Executive Officer
Carter Keller Chief Operating Officer
Everett Meyer Ph.D Co-Founder & Medical Advisor
Jennifer Keller Head, Marketing
Matthew Spindler Head, Strategic Alliances

GigaGen Board Members (1)

NameRepresentingRoleSinceContact
Info
Charles Wilson Ph.DSelfBoard Member000 0000
Charles Wilson Ph.D Board Member Self
Request full access to PitchBook